tiprankstipranks
M1 Kliniken AG (DE:M12)
XETRA:M12
Germany Market
Want to see DE:M12 full AI Analyst Report?

M1 Kliniken AG (M12) AI Stock Analysis

13 Followers

Top Page

DE:M12

M1 Kliniken AG

(XETRA:M12)

Select Model
Select Model
Select Model
Outperform 82 (OpenAI - 5.2)
Rating:82Outperform
Price Target:
€22.50
▲(23.90% Upside)
Action:Reiterated
Date:07/10/26
The score is driven primarily by strong financial performance (growing revenue and significantly improved earnings, low leverage, and strong recent cash generation). Technicals are supportive with a clear trend above major moving averages and positive MACD, though short-term signals are mixed due to very low Stoch. Valuation adds support via a reasonable P/E and a high dividend yield.
Positive Factors
Strong cash generation
Sustained operating and free cash flow growth shows durable cash conversion from patient-paid services and product sales. Reliable internal cash generation supports reinvestment in clinics, equipment, dividends or M&A, and lowers dependency on external financing over multiple quarters.
Negative Factors
Margin volatility / limited 2025 margin detail
Notable swings in gross and EBITDA margins across 2023–2024 and sparse 2025 margin disclosure reduce visibility into sustainable profitability. For an elective-services model sensitive to procedure mix and supplier pricing, persistent margin volatility complicates long-term planning and capital allocation.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Sustained operating and free cash flow growth shows durable cash conversion from patient-paid services and product sales. Reliable internal cash generation supports reinvestment in clinics, equipment, dividends or M&A, and lowers dependency on external financing over multiple quarters.
Read all positive factors

M1 Kliniken AG (M12) vs. iShares MSCI Germany ETF (EWG)

M1 Kliniken AG Business Overview & Revenue Model

Company Description
M1 Kliniken AG, a Berlin, Germany-based entity established in 2007 and operating as a subsidiary of MPH Health Care AG, manages medical facilities dedicated to aesthetic and plastic surgery across Germany, Austria, the Netherlands, Switzerland, th...
How the Company Makes Money
M1 Kliniken AG generates revenue mainly through patient-paid medical services delivered in its own clinic network. This includes consultation fees and the provision of elective aesthetic treatments and procedures (e.g., minimally invasive aestheti...

M1 Kliniken AG Financial Statement Overview

Summary
Strong overall fundamentals: consistent revenue growth (2022–2025) and materially higher net income versus 2022, supported by a conservatively financed balance sheet (very low debt-to-equity by 2024) and strong recent operating/free cash flow. Main risks are margin visibility/volatility (notably across 2023–2024 and limited 2025 margin detail) and cash-flow volatility highlighted by the 2023 trough.
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
82
Very Positive
BreakdownDec 2025Mar 2025Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue364.30M339.18M316.32M285.29M314.61M
Gross Profit47.43M63.60M32.47M21.72M26.06M
EBITDA40.49M33.44M21.79M16.07M19.78M
Net Income22.13M16.02M10.27M4.32M8.91M
Balance Sheet
Total Assets189.29M187.87M212.95M197.02M198.11M
Cash, Cash Equivalents and Short-Term Investments42.00M23.69M22.76M47.50M49.12M
Total Debt10.26M10.42M17.04M19.67M30.93M
Total Liabilities39.28M53.65M69.73M53.97M58.21M
Stockholders Equity119.93M106.10M113.25M95.52M95.03M
Cash Flow
Free Cash Flow37.84M29.55M6.80M19.25M14.32M
Operating Cash Flow37.95M30.55M7.81M21.02M15.66M
Investing Cash Flow-645.81K-5.67M-9.36M-1.77M213.19K
Financing Cash Flow-13.41M-30.44M-14.81M-21.97M4.03M

M1 Kliniken AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price18.16
Price Trends
50DMA
17.27
Positive
100DMA
15.87
Positive
200DMA
15.63
Positive
Market Momentum
MACD
0.30
Negative
RSI
55.00
Neutral
STOCH
15.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M12, the sentiment is Positive. The current price of 18.16 is above the 20-day moving average (MA) of 17.43, above the 50-day MA of 17.27, and above the 200-day MA of 15.63, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 55.00 is Neutral, neither overbought nor oversold. The STOCH value of 15.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:M12.

M1 Kliniken AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
€338.07M15.0818.60%2.80%7.40%38.17%
74
Outperform
€162.00M27.9924.05%33.49%81.79%
63
Neutral
€23.73B16.007.76%2.05%4.22%248.36%
63
Neutral
€191.90M6.7611.90%1.12%5.13%11.89%
57
Neutral
€903.67M22.503.04%0.77%6.06%0.93%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
45
Neutral
€20.34M-1.2821.40%3.53%-5.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:M12
M1 Kliniken AG
18.10
5.05
38.64%
DE:FRE
Fresenius SE & Co. KGaA
42.57
1.73
4.23%
DE:MED
MEDICLIN
4.04
1.17
40.82%
DE:RHK
RHON-KLINIKUM AG
13.50
1.59
13.39%
DE:MAK
MATERNUS-Kliniken AG
0.97
-0.11
-10.19%
DE:LIK
Limes Schlosskliniken AG
540.00
188.82
53.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 10, 2026